The following Gynecologic Oncology Group member institutions participated in this study: University of Alabama at Birmingham, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, Wayne State University, University of Minnesota Medical School, Emory University Clinic, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, Wake Forest University School of Medicine, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke's Medical Center, SUNY Downstate Medical Center, University of Kentucky, Community Clinical Oncology Program, The Cleveland Clinic Foundation, Johns Hopkins Oncology Center, State University of New York at Stony Brook, Eastern Pennsylvania GYN/ONC Center, P.C., Washington University School of Medicine, Cooper Hospital/University Medical Center, Columbus Cancer Council, University of Massachusetts Medical School, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, Tacoma General Hospital, Thomas Jefferson University Hospital, Case Western Reserve University, Tampa Bay Cancer Consortium, North Shore University Hospital, Gynecologic Oncology Network, Oregon Health Sciences University, University of Southern California at Los Angeles, University of Miami School of Medicine, Stanford University Medical Center, Eastern Virginia Medical School, University of Arizona Health Science Center, Mayo Clinic, and Long Island Jewish Medical Center.
Reclassification of serous ovarian carcinoma by a 2-tier system†
A Gynecologic Oncology Group Study
Article first published online: 9 NOV 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 12, pages 3087–3094, 15 June 2012
How to Cite
Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., Baergen, R., Emerson, R. E., Steinhoff, M., Behmaram, B., Rasty, G. and Gershenson, D. M. (2012), Reclassification of serous ovarian carcinoma by a 2-tier system. Cancer, 118: 3087–3094. doi: 10.1002/cncr.26618
- Issue published online: 4 JUN 2012
- Article first published online: 9 NOV 2011
- Manuscript Accepted: 7 SEP 2011
- Manuscript Revised: 25 AUG 2011
- Manuscript Received: 29 JUN 2011
- 10How to Manage, Analyze, and Interpret Survey Data. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002..
- 11Modeling Survival Data in Medical Research. 2nd ed. New York, NY: Chapman & Hall/CRC; 2003..
- 23Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29: 218-224., , , et al.